Beijing VDJ Bio Closes Series B Round

Beijing VDJ Bio announced the completion of the B round of financing, led by SDIC Ventures, joint ventures of Jiuyou Capital, Lotus Lake Capital, Tao Capital, and Hongbo Ventures, with Start Point Advisors acting as the exclusive for this round financial consultant.

This is the third financing completed by VDJ Bio since its establishment. The first two rounds were completed in 2015 and 2017 respectively. According to Li Ziqiang, the founder of VDJ Bio, the company's current round of financing will be mainly used for clinical phase 1/2 research on the company's three core pipelines.

VDJ Bio is a platform company focusing on the research and development of innovative antibody drugs for autoimmune diseases. The company has a self-developed antibody screening optimization platform, a fusion protein CMC platform and an in vitro activity evaluation platform, which can be developed for existing clinical targets. Bio-super’s monoclonal antibody/antibody fusion protein drugs focus on the development of a new generation of monoclonal antibody drugs for the treatment of autoimmune diseases with high efficacy, high safety and low production cost.

From building a core technology platform, to optimizing and screening drug candidates, to pre-clinical pilot production, every step VDJ Bio has taken is step by step. The founder Li Ziqiang emphasized that VDJ Bio is mainly focused on the research and development of autoimmune diseases. The research and development cycle of such new drugs is longer. The company began to deploy in this field earlier, and the corresponding product pipeline has applied for international patents.